The majority of patients resort to Depakene, a trademarked version of the generic equivalent Valproic acid which is promoted and marketed by Abbott Laboratories. The chief use of Depakene is to care for seizures induced by epilepsy (a brain disorder) and other seizure problems. Some affected persons may also take this medication to thwart migraines or to check episodes of manic actions. But, taking Valproic acid poses its users the risk of severe impairment to liver. More common side effects of the drug are nausea and tremble.

Drug Indications

Depakene (Valproic acid) is indicated as monotherapy and adjunctive or combination therapy in the intervention of patients with complicated fractional seizures that take place either in seclusion or in conjunction with other kinds of seizures. Valproic acid is also suggested for application as both solitary and adjunctive remedy in the treatment of uncomplicated and complex absence seizures, and adjunctively in individuals with several seizure cases that comprise absence seizures (the happenings of a sudden, temporary loss or damage of cognizance).

Simple or pure absence is specified as very short clouding of the cortical region or loss of awareness followed by specific widespread epileptic releases devoid of other noticeable medical complications. Complex absence refers to the condition when other abnormalities also exist.

Dosage & Administration

Depakene (Valproic acid) is given by mouth. It is prescribed as singular and adjunctive therapy in complicated partial seizures in grownups and children up to the age of 10 years, and in straightforward and complex absence seizures. As the dosage of Depakene is quantified in the upward direction, absorptions of phenobarbital (a long-acting barbiturate applied as a tranquilizer), carbamazepine, and/or phenytoin (an anticonvulsant drug for epilepsy which is not a sedative) may be influenced.

Depakene has not been methodically researched as an initial therapy. Affected persons must begin treatment at 10 to 15 mg per kg a day. The dosage must be raised by 5 to 10 mg per kg a week to attain optimum clinical outcome.

In order to carry out the process of conversion to monotherapy, patients must commence therapy at 10 to 15 mg per kg a day. The dosage ought to be increased by 5 to 10 mg/kg/week to accomplish optimum clinical outcome. Generally, optimum clinical result is attained at everyday doses lower than 60 mg per kg a day. The same dosing instructions are followed in case of adjunctive therapy of Depakene too.

Common Side Effects

More than 25 percent of affected persons taking medicines that comprised Depakene's active ingredient (Valproic acid) throughout clinical tests went through nausea, purging, headaches, common weakness, sleepiness, wooziness and trembling. More than 5 percent of participants in trials reported looseness of the bowels, loss of appetency, pain in the abdomen, fever, difficult emptying the bowels, hazy eyesight, loss of visual concentration, mood switches, influenza-like signs, loss of hair, loss of weight, amnesia, unusual thinkings and absence of muscle synchronization. The occurrence of side effects was directly proportional to the dose of Depakene.

Less common Side Effects

Less than one percent of patients using Depakene (Valproic acid) have gone through reductions in red blood cell level, subnormal body temperature (i.e., hypothermia) or considerable rises in blood absorptions of ammonia, a medical disorder called hyperammonemia that can result in brain swelling. An additional rare side effect from Depakene has been a life-threatening allergy noticeable by fever, skin rash, puffed up lymph nodes and pain in the joints.